Key facts
- It has raised $330K; the latest was Early Stage VC in Apr 2025.
- Notable investors include EIT Food, FS Life Science Investment, Climate Founders, Technologiegründerfonds Sachsen, biotope by VIB.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Primogene
- ·The full record, as it builds
Funding rounds
No funding rounds for Primogene are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Primogene
Developer of bioactive nutritional components designed to support the dietary needs of vulnerable infants. The company replicates functional elements found in human breast milk through precision biomanufacturing, incorporating clinically relevant molecules that aid immune system development and digestive health, produced under controlled conditions to ensure purity and safety, enabling neonatal care providers to improve nutritional outcomes, reduce risk of complications, and support early-stage growth and development in premature and at-risk newborns.
- Sector
- Healthcare
- HQ
- Leipzig, Germany
- Founded
- 2023
- Employees
- 6
- Website
- primogene.bio/
- Ownership
- Privately Held (backing)
Primogene doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Primogene shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Primogene in its N-PORT filings yet. We sweep new filings monthly.